Drug Profile
Immune globulin - LFB Biotechnologies
Alternative Names: Clairyg; I10E; IqymuneLatest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator LFB Biotechnologies
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Autoimmune disorders; Immunodeficiency disorders
- Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease
Most Recent Events
- 06 Jan 2023 Discontinued - Phase-III for Chronic inflammatory demyelinating polyradiculoneuropathy in Spain, Italy, France, Tunisia, Germany, Germany, United Kingdom, Turkey (IV)
- 18 Sep 2020 No development reported - Phase-III for Chronic inflammatory demyelinating polyradiculoneuropathy in Germany, Turkey, Tunisia, France, Italy, Spain and United Kingdom (IV)
- 29 Sep 2017 LFB Biotechnologies completes the phase III PRISM trial in Chronic inflammatory demyelinating polyradiculoneuropathy in Germany, Turkey, Tunisia, United Kingdom, France, Italy and Spain (IV) (EudraCT2013-005557-73) (NCT02293460)